Drug Profile
Ear disorder therapeutic
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator DURECT Corporation
- Developer DURECT Corporation; NeuroSystec Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ear disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Ear disorders in USA
- 10 Jul 2007 Phase-I clinical trials in Ear disorders in USA (unspecified route)